Guidelines for the treatment of psoriatic arthritis with biologics

91 Cherouvim EP, Zintzaras E, Boki KA, Moutsopoulos HM, Manoussakis MN. Infliximab Therapy for
Patients With Active and Refractory Spondyloarthropathies at the Dose of 3 mg/kg: A 20‐Month Open
Treatment. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
2004;10(4):162‐8.
92 Covelli M, Scioscia C, Iannone F, Lapadula G. Repeated infusions of low‐dose infliximab plus
methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
Clinical and experimental rheumatology 2005;23(2):145‐51.
93 De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High‐dose initiation of etanercept in
psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J Dermatolog
Treat 2006;17(6):355‐8.
94 Bello S, Bonali C, Serafino L, Di Giuseppe P, Minosi A, Terlizzi N. [Intra‐articular therapy with infliximab
in psoriatic arthritis: efficacy and safety in refractory monoarthritis]. Reumatismo 2010;62(1):46‐50.
95 Conti F, Ceccarelli F, Priori R, Iagnocco A, Signore A, Valesini G. Intra‐articular infliximab in patients
with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical
efficacy extended to patients on systemic anti‐tumour necrosis factor alpha. Ann Rheum Dis 2008;67(12):1787‐
90.
96 Arnold EL, Khanna D, Paulus H, Goodman MP. Acute injection site reaction to intraarticular etanercept
administration. Arthritis and rheumatism 2003;48(7):2078‐9.
97 Bliddal H. Intraarticular injection of anti‐tumor necrosis factor: Comment on the letter by Arnold et al.
Arthritis and rheumatism 2004;50(6):2037‐8.
98 Haroon M, O'Gradaigh D. Efficacy and safety of combining intra‐articular methylprednisolone and
anti‐TNF agent to achieve prolonged remission in patients with recurrent inflammatory monoarthritis. Joint,
bone, spine : revue du rhumatisme 2010;77(3):232‐4.
99 Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis
2008;67(11):1647‐8.
100 Nocturne G, Dougados M, Constantin A, et al. Rituximab in the spondyloarthropathies: data of eight
patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010;69(2):471‐
2.
101 Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal
antibody, for psoriatic arthritis: randomised, double‐blind, placebo‐controlled, crossover trial. Lancet
2009;373(9664):633‐40.
102 Santos‐Juanes J, Coto‐Segura P, Mas‐Vidal A, Galache Osuna C. Ustekinumab induces rapid clearing of
erythrodermic psoriasis after failure of antitumour necrosis factor therapies. The British journal of
dermatology 2010;162(5):1144‐6.
103 McInnes I, Sieper J, Braun J, et al. Anti‐interleukin 17A monoclonal antibody secukinumab reduces
signs and symptoms of psoriatic arthritis in a 24‐week multicenter, double‐blind, randomized, placebocontrolled
trial. Arthritis Rheum 2011;63(10 (supplement)):S306.
104 Canete JD, Celis R, Hernandez V, Pablos JL, Sanmarti R. Synovial immunopathological changes
associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis
2010;69(5):935‐6.
26